I. Kev Taw Qhia: Cov Tshuaj Tiv Thaiv -Kev Muaj Peev Xwm Cancer ntawm Metformin, Cov Tshuaj Miracle rau Glycemic Control
Ua ntej sib xyaw ua ke hauv 1922 thiab tau txais kev pom zoo hauv xyoo 1957, metformin tseem yog lub ntiaj teb cov kws kho mob dav dav tshaj plaws rau hom 2 mob ntshav qab zib hnub no. Kev nce qib tsis tu ncua hauv kev tshawb fawb hauv paus tau ua pov thawj ntau yam uas tau hais tias metformin tawm dag zog ua haujlwm inhibiting qog cell proliferation, endowing nws nrog broad zeem muag rau anti- qog kev tshawb fawb thiab kev loj hlob. Ib txoj kev tshawb nrhiav tus qauv nas uas tsis ntev los no tau luam tawm hauvXwmmuab lub tswv yim tshiab rau kev kho ua ke nrog metformin los tawm tsam triple -mob qog noj ntshav tsis zoo.
II. Kev tshawb fawb tshiab hauvXwm: Heme Ua ke nrog Metformin rau Kev Kho Mob Lub Hom Phiaj ntawm Triple -Kev Mob Cancer Breast
2.1 Keeb kwm ntawm Heme thiab Nws Lub Hom Phiaj BACH1
Heme yog thawj zaug crystallized thiab cais tawm los ntawm cov ntshav hauv xyoo 1853, thiab tam sim no tau txais kev kho mob tsuas yog rau cov teeb meem cuam tshuam nrog heme biosynthesis tsis zoo. Txoj kev tshawb no yog thawj zaug los txheeb xyuas BACH1 (BTB thiab CNC homology 1), ib qho kev hloov pauv, raws li kev tiv thaiv - qog lub hom phiaj ntawm heme. BACH1 tau qhia ntau heev hauv triple-mob qog noj ntshav tsis zoo (TNBC) thiab ua raws li cov ntsiab lus tseem ceeb ntawm cov qog nqaij hlav metastasis; siab BACH1 qhia feem ntau kwv yees kwv yees tus neeg mob tsis zoo. Qhov kev hloov pauv no tswj hwm cov metabolism hauv mitochondrial los ntawm kev khi rau cov txheej txheem DNA tshwj xeeb txhawm rau txhawm rau hloov pauv cov noob muaj feem xyuam rau cov saw hlau mitochondrial electron thauj khoom, yog li txiav tawm ib txoj hauv kev loj zog rau cov qog hlwb. Ntxiv mus, BACH1 tsis yog lub hom phiaj tseem ceeb rau kev muaj sia nyob ntawm tes, lub ntsiab lus tsom inhibition ntawm cov protein no tuaj yeem ua rau qis - tshuaj lom neeg kev kho mob.
2.2 Mechanism of Combination Therapy and Outcomes of Animal Experiments
Hauv vitro cellular kev soj ntsuam pom tau hais tias kev kho heme downregulates BACH1 qhia thiab quab yuam metabolic reprogramming hauv qog hlwb. Tsim los ntawm kev tshawb fawb tshawb fawb ua ntej, pab pawg tshawb fawb tau hais txog qhov kev xav: cov qog hlwb uas hloov pauv txoj hauv kev metabolic ua rau muaj kev cuam tshuam ntau dua rau metformin -kev kho mob ntawm kev ua pa ntawm mitochondrial. Tom qab nas xenograft qog ua qauv tau lees paub qhov kev xav no: kev sib xyaw ua ke ntawm heme ntxiv rau metformin tau zoo inhibited kev loj hlob ntawm triple-cov qog mis tsis zoo.
2.3 Kev taw qhia rau Cov Tshuaj Kho Mob Tus Kheej thiab Kev Pom Zoo ntawm Broad-Spectrum Anti-Cancer Application
Txoj kev tshawb no muab tso rau pem hauv ntej stratified therapeutic moj khaum:
Cov neeg mob uas tsis tshua muaj BACH1 qhia thiab kev qhia siab ntawm mitochondrial -cov noob muaj feem cuam tshuam cov lus teb kho tau zoo rau metformin monotherapy;
Cov neeg mob uas muaj BACH1 siab thiab kev qhia qis ntawm mitochondrial-cov noob muaj feem cuam tshuam yog qhov muaj peev xwm tiv taus metformin. Co- kev tswj hwm nrog heme thim rov qab cov tshuaj tiv thaiv thiab kho cov qog rhiab heev rau metformin.
Cov kws tshawb fawb tau hais tias BACH1 overexpression tsis yog rau triple-mob cancer mis; Cov qib siab ntawm cov protein no kuj raug kuaj pom hauv ntau yam mob xws li mob ntsws cancer, mob raum, mob qog noj ntshav, mob qog nqaij hlav prostate thiab mob myeloid leukemia. Yog li, qhov kev kho mob zoo li no tau cog lus rau kev nthuav dav thoob plaws ntau hom mob qog noj ntshav. Txoj kev tshawb no tseem ua rau lub ntiaj teb thawj qhov kev tshawb fawb txog kev tiv thaiv -cov qog nqaij hlav sib txuas ua ke nrog metformin nrog heme.
III. Tshawb nrhiav hauvNature Communications: Txhim kho Triple Combination Therapy for Breast Cancer Incorporating Metformin
3.1 Lub Hom Phiaj Tom Qab: MYC-Mediated Metabolic Vulnerabilities nyob rau hauv cov qog
MYC oncogene yog overexpressed nyob rau hauv ntau tshaj 40% ntawm cov qog nqaij hlav cancer ntawm lub mis, ua rau metabolic tsis xws luag nyob rau hauv cov qog hlwb uas ua rau cov qog nqaij hlav cancer prone rau apoptosis. Kev siv tus cwj pwm no, pab pawg tshawb fawb los ntawm University of Helsinki hauv Finland tau tshawb nrhiav cov tshuaj tshiab ua ke. Venetoclax, BCL-2 inhibitor tau pom zoo los ntawm FDA rau qee yam hematological malignancies, induces qog cell apoptosis tab sis tseem tsis tau txais kev pom zoo rau kev qhia txog mob qog noj ntshav. Cov kev sim tshuaj ntsuam tau qhia tiasmetforminamplifies pro-apoptotic nyhuv ntawm venetoclax.
3.2 Kev ua tau zoo thiab kev txwv ntawm Dual-Cov Kev Cai Tshuaj: Metformin ntxiv rau Venetoclax
Hauv vitro cell kab lis kev cai, cov qauv tsiaj txhu mob qog noj ntshav thiab cov neeg mob- tau txais cov qauv qog nqaij hlav tag nrho tau lees paub tias kev sib xyaw ntawm metformin thiab venetoclax siv MYC-induced metabolic vulnerabilities kom tshem tawm cov qog nqaij hlav hauv lub mis thiab tiv thaiv cov qog nqaij hlav. Txawm li cas los xij, qhov ob - tus neeg sawv cev tswj hwm no muaj cov kev txwv tseem ceeb. Hauv cov qauv nas, kev kho mob ua ke tsuas yog ua tiav kev tswj cov qog ib ntus, nrog rau cov qog sai sai thaum tshem tawm cov tshuaj. Mechanistic tsom xam tau qhia tias dual -tshuaj kho mob ua rau mob hnyav heev ntawm cov qog- tua cov lymphocytes, thaum lub cev tsis muaj zog tiv thaiv kab mob pom PD-1 qhia siab, tsim kom muaj kev tiv thaiv kab mob microenvironment.
3.3 Triple Combination Therapy: Metformin + Venetoclax + PD-1 Antibody
Hauv kev teb rau kev hloov kho lub cev tiv thaiv kab mob microenvironment, pab pawg tshawb fawb tau koom nrog PD-1 cov tshuaj tiv thaiv kab mob los tsim kho triple therapeutic regimen:
Metformin ua ke nrog venetoclax: txo cov qog nqaij hlav, ua rau mob qog noj ntshav ntawm tes apoptosis thiab activates cytotoxic lymphocytes;
PD-1 cov tshuaj tiv thaiv kab mob: txo cov tshuaj tiv thaiv kab mob thiab txhawb nqa cov qog ua haujlwm ntawm lymphocytes. Cov kev sim tsiaj tau tshawb pom tias qhov kev kho mob triple ua ke ua rau lub neej muaj sia nyob ntawm cov qog-cov kabmob nas piv nrog kev kho mob monotherapy lossis kev siv tshuaj ob zaug. Tag nrho peb tus neeg sawv cev hauv qhov kev tswj hwm no yog cov khoom lag luam pom zoo, tsim kom muaj txiaj ntsig zoo rau kev hloov pauv sai rau tib neeg kev sim tshuaj.
IV. Ntxiv keeb kwm yav dhau: Kev kho mob tam sim no toj roob hauv pes ntawm Triple-Kev mob qog noj ntshav mis tsis zoo
Triple-mob qog noj ntshav tsis zoo (TNBC) suav txog 15% txog 20% ntawm tag nrho cov mob qog noj ntshav mis, nrog rau cov poj niam hluas ntau dua. Nws yog tus cwj pwm los ntawm kev pheej hmoo rov ua dua tshiab, propensity rau cov metastasis nyob deb thiab cov neeg tuag coob heev. Tam sim no, cov neeg mob feem ntau tsuas tuaj yeem tau txais cov tshuaj khomob ib txwm siv, uas feem ntau ua rau cov tshuaj tiv thaiv thiab ua rau muaj qhov pom zoo tag nrho. Yav dhau los, lubNew England Journal of Medicine (NEJM)luam tawm qhov tseem ceeb ntawm kev kho mob: kev sib xyaw ntawm atezolizumab (a PD-L1 antibody) thiab albumin- khi paclitaxel tau txais kev pom zoo los ntawm FDA, dhau los ua lub ntiaj teb thawj zaug - kab phiaj xwm kev tiv thaiv kab mob qhia rau triple- mob qog noj ntshav tsis zoo.
V. Xaus
Ob qhov kev tshawb fawb siab - cuam tshuam tau tsim ob txoj hauv kev sib xyaw ua ke sib txawv rau kev kho mob qog noj ntshav hauv lub mis ntawm metformin: heme-raws li kev tswj hwm lub hom phiaj BACH1 los hloov kho cov metabolism hauv mitochondrial, thaum triple- tus neeg saib xyuas kev kho mob siv MYC-tsav cov tshuaj tiv thaiv kab mob metabolic. Raws li ib xyoo caum classics - qub chaw muag tshuaj, metformin boasts zoo- tsim kom muaj kev ruaj ntseg profiles thiab tswj cov nqi kho mob. Nws xav tias yuav ua kom ceev cov kev kho mob txhais lus tshiab ntawm kev kho mob tshiab rau ntau yam mob qog noj ntshav ntawm lub mis, thiab ua raws li -cov ntaub ntawv los ntawm cov kev sim tshuaj muaj feem cuam tshuam tau txais kev saib xyuas.
